scholarly article | Q13442814 |
review article | Q7318358 |
P356 | DOI | 10.1016/S0168-8227(11)70012-2 |
P698 | PubMed publication ID | 21864750 |
P50 | author | Daniel H van Raalte | Q89048137 |
Michaela Diamant | Q108578052 | ||
P2860 | cites work | One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial | Q24656644 |
Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose | Q28261829 | ||
Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells | Q28473974 | ||
Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis | Q28570314 | ||
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 | ||
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. | Q33300966 | ||
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin | Q33804747 | ||
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
Minireview: Secondary beta-cell failure in type 2 diabetes--a convergence of glucotoxicity and lipotoxicity | Q34109834 | ||
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
Islet beta cell failure in type 2 diabetes | Q34698810 | ||
Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets | Q34796756 | ||
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes | Q35085591 | ||
Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities | Q36321572 | ||
Beta-cell preservation with thiazolidinediones | Q36628951 | ||
Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? | Q36678584 | ||
beta-cell failure in diabetes and preservation by clinical treatment | Q36757992 | ||
Glucolipotoxicity: fuel excess and beta-cell dysfunction. | Q36861036 | ||
Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration | Q36899584 | ||
The role for endoplasmic reticulum stress in diabetes mellitus | Q37019672 | ||
Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins | Q37091579 | ||
Preservation of beta-cell function by targeting beta-cell mass | Q37116279 | ||
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes | Q37164521 | ||
Glucolipotoxicity of the pancreatic beta-cell: myth or reality? | Q37269512 | ||
An update on lipotoxic endoplasmic reticulum stress in pancreatic beta-cells | Q37269518 | ||
The sensitivity of pancreatic beta-cells to mitochondrial injuries triggered by lipotoxicity and oxidative stress. | Q37269525 | ||
Transient oxidative stress damages mitochondrial machinery inducing persistent beta-cell dysfunction | Q37358162 | ||
Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. | Q37429250 | ||
Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes | Q38349512 | ||
The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice | Q38363214 | ||
Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6. | Q39959315 | ||
Rosiglitazone counteracts palmitate-induced beta-cell dysfunction by suppression of MAP kinase, inducible nitric oxide synthase and caspase 3 activities | Q39971422 | ||
Glucagon-like peptide-1 prevents beta cell glucolipotoxicity | Q40565084 | ||
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes | Q42450726 | ||
Prolonged increase of plasma non-esterified fatty acids fully abolishes the stimulatory effect of 24 hours of moderate hyperglycaemia on insulin sensitivity and pancreatic beta-cell function in obese men. | Q42455250 | ||
Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes | Q42469053 | ||
Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes | Q42489695 | ||
Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells | Q42490936 | ||
Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea | Q42505421 | ||
Islets in type 2 diabetes: in honor of Dr. Robert C. Turner | Q43248047 | ||
Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death | Q43596005 | ||
Lipotoxicity in human pancreatic islets and the protective effect of metformin | Q43869352 | ||
Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. | Q43972538 | ||
Acute elevation of NEFA causes hyperinsulinemia without effect on insulin secretion rate in healthy human subjects. | Q44038630 | ||
Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. | Q44328946 | ||
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes | Q44526985 | ||
Short-term intensive insulin therapy in newly diagnosed type 2 diabetes | Q44865579 | ||
Sulfonylurea induced beta-cell apoptosis in cultured human islets | Q45105959 | ||
Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function | Q45124452 | ||
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 | ||
Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. | Q45142823 | ||
Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets | Q45218553 | ||
Increased insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis in Wfs1 knockout mice | Q46134848 | ||
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes | Q46484235 | ||
Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. | Q46576386 | ||
Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? | Q46774741 | ||
Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus | Q46804042 | ||
Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database | Q46841507 | ||
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes | Q46953451 | ||
Relationship between beta-cell mass and fasting blood glucose concentration in humans | Q46966775 | ||
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes | Q47296454 | ||
Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions | Q51015452 | ||
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. | Q51468797 | ||
Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. | Q51478323 | ||
Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. | Q51584824 | ||
Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells. | Q53544467 | ||
The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose | Q57504429 | ||
Elevation of plasma fatty acids by ten-hour intralipid infusion has no effect on basal or glucose-stimulated insulin secretion in normal man | Q73707200 | ||
Free fatty acid-induced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo | Q80838553 | ||
P921 | main subject | type 2 diabetes | Q3025883 |
P304 | page(s) | S37-46 | |
P577 | publication date | 2011-08-01 | |
P1433 | published in | Diabetes Research and Clinical Practice | Q15750054 |
P1476 | title | Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy? | |
P478 | volume | 93 Suppl 1 |
Q28542553 | A combined analysis of 48 type 2 diabetes genetic risk variants shows no discriminative value to predict time to first prescription of a glucose lowering drug in Danish patients with screen detected type 2 diabetes |
Q27301094 | Antidiabetic Effect of Galantamine: Novel Effect for a Known Centrally Acting Drug |
Q39871850 | Bariatric surgery as a treatment option in patients with type 2 diabetes mellitus |
Q38165184 | Diabetes and beta cell function: from mechanisms to evaluation and clinical implications |
Q35853171 | Early Pregnancy Maternal Lipid Profiles and the Risk of Gestational Diabetes Mellitus Stratified for Body Mass Index |
Q35932373 | Edible Bird's Nest Prevents High Fat Diet-Induced Insulin Resistance in Rats |
Q35937965 | Effect of Cosmos caudatus (Ulam raja) supplementation in patients with type 2 diabetes: Study protocol for a randomized controlled trial. |
Q41841136 | Effects of berberine on amelioration of hyperglycemia and oxidative stress in high glucose and high fat diet-induced diabetic hamsters in vivo |
Q38007405 | Effects of glucocorticoids and exercise on pancreatic β-cell function and diabetes development |
Q43128441 | Eight Weeks of Cosmos caudatus (Ulam Raja) Supplementation Improves Glycemic Status in Patients with Type 2 Diabetes: A Randomized Controlled Trial |
Q51367458 | Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. |
Q37102291 | Fatty Acid Transport Proteins: Targeting FATP2 as a Gatekeeper Involved in the Transport of Exogenous Fatty Acids |
Q47156198 | Fatty Acids, Antioxidants and Physical Activity in Brain Aging |
Q38715488 | G protein-coupled receptors as targets for anti-diabetic therapeutics |
Q97075301 | Green Coffea arabica Extract Ameliorates Testicular Injury in High-Fat Diet/Streptozotocin-Induced Diabetes in Rats |
Q38356098 | High fat programming of beta cell compensation, exhaustion, death and dysfunction. |
Q53743821 | Hypoglycemic and Hypolipidemic Effects of Leucine, Zinc, and Chromium, Alone and in Combination, in Rats with Type 2 Diabetes. |
Q26860847 | Islet inflammation: a unifying target for diabetes treatment? |
Q42374044 | Phenolic constituents and modulatory effects of Raffia palm leaf (Raphia hookeri) extract on carbohydrate hydrolyzing enzymes linked to type-2 diabetes. |
Q51733555 | Pioglitazone Attenuates Palmitate-Induced Inflammation and Endoplasmic Reticulum Stress in Pancreatic β-Cells. |
Q34442232 | Protective antioxidant and antiapoptotic effects of ZnCl2 in rat pancreatic islets cultured in low and high glucose concentrations |
Q36184201 | Regular physical exercise as a strategy to improve antioxidant and anti-inflammatory status: benefits in type 2 diabetes mellitus. |
Q38044705 | Role of inflammatory mechanisms in pathogenesis of type 2 diabetes mellitus. |
Q85311508 | Rosiglitazone protects against palmitate-induced pancreatic beta-cell death by activation of autophagy via 5'-AMP-activated protein kinase modulation |
Q42374211 | Sodium fluorocitrate having protective effect on palmitate-induced beta cell death improves hyperglycemia in diabetic db/db mice |
Q26744217 | Stressing diabetes? The hidden links between insulinotropic peptides and the HPA axis |
Q26852726 | Targeting inflammation in diabetes: Newer therapeutic options |
Q35830892 | Targeting metabolic disorders by natural products |
Q95481300 | WITHDRAWN: RIP140 mediates hyperglycemia-induced glucotoxicity in β-cells via the activation of JNK and ERK1/2 signaling pathways |